%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
2013-10-23T20:44:50+03:00
2013-10-23T20:44:50+03:00
2013-10-23T20:44:50+03:00
application/pdf
bs-0195R-A647
uuid:a5d3ef13-ed2c-45a0-8f59-0951d83704f1
uuid:da3e1b92-9bf1-40d0-8e62-0fabc9bdd3c4
Acrobat Web Capture 9.0
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>
endobj
11 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/Type/Page>>
endobj
12 0 obj
[32 0 R]
endobj
13 0 obj
<>stream
/CS0 cs 1 scn
10 815.726 574.5 -735.891 re
f
BT
0.2 scn
/TT0 1 Tf
6.6416 0 0 6.6416 21.2908 767.2422 Tm
(www.biossusa.com)Tj
0 -1.5 TD
(support@biossusa.com)Tj
-0.012 Tw 0 -1.5 TD
[(800.501.7654)-34( )1([DOMESTIC])]TJ
0 -1.5 TD
[(+1.781.569.5821)-57( )1([INTERNATIONAL])]TJ
ET
q
/GS0 gs
141.4664764 0 0 -79.6994171 438.3843994 810.412735 cm
/Im0 Do
Q
BT
0 scn
/TT1 1 Tf
0 Tw 9.2983 0 0 9.2983 21.2908 715.4376 Tm
[(bs)-67(-)-69(0195R)-12(-)-69(A647)]TJ
/TT0 1 Tf
-0.04 Tw 7.3058 0 0 7.3058 28.5965 668.9462 Tm
[(Conjugated)-58( Primary)-1( Antibodies)]TJ
/TT1 1 Tf
0 Tw 0 -2.091 TD
(Background:)Tj
/TT0 1 Tf
-0.04 Tw 0 -1.455 TD
[(This)-1( protein)-79( is)-52( a)-20( cell)-9( adhesion)-62( molecule)-88( expressed)-23( on)-81( platelets)-25( and at)-50( endothelial)-8( cell)-9( intercellular)-58( junctions.)-1( Type)]TJ
0 -1.455 TD
[(I)-81( membrane)-90( protein.)-48( SIZE:)-51( 738)-89( amino)-32( acids;)-68( 82536)-88( Da.)-39( SUBCELLULAR)-29( LOCATION:)2( Membrane;)-78( Single)-75(-)-1(pass)-30( type)]TJ
0 -1.455 TD
[(I)-81( membrane)-90( protein.)-48( TISSUE)-76( SPECIFICITY:)-66( Long)-30( isoform)-85( predominates)-7( all)-17( tissues)-15( examined,)-81( isoform)-85( Delta12)]TJ
0 -1.455 TD
[(was)-14( detected)-5( only)-81( in)-31( trachea)-75( and isoform)-85( Delta14)-70(-)-1(15)-90( only)-81( in)-31( lung,)-72( isoform)-85( Delta14)-71( was)-14( detected)-5( in)-31( all)-17( tissues)]TJ
T*
[(examined)-21( with)-46( the)-36( strongest)-82( expression)-45( in)-31( heart.)-30( PTM:)-13( Phosphorylated)-41( on)-81( Ser)-11( and Tyr)-13( residues)-83( after)-28( cellular)]TJ
0 -1.455 TD
[(activation.)-6( SIMILARITY:)-47( Contains)-24( 6)-90( Ig)-74(-)-1(like)-63( C2)-35(-)-1(type)-89( \(immunoglobulin)-52(-)-1(like\))-44( domains.)]TJ
0 -1.455 TD
[(CD31,)-53( also)-75( known)-10( as)-29( platelet)-17( endothelial)-8( cell)-9( adhesion)-62( molecule)-88( 1)-90( \(PECAM1\),)-28( is)-52( a)-20( type)-89( I)-82( integral)-50( membrane)]TJ
0 -1.455 TD
[(glycoprotein)-67( and a)-20( member)-82( of)-48( the)-37( immunoglobulin)-71( superfamily)-9( of)-48( cell)-10( surface)-79( receptors.)-42( It)-20( is)-52( found)-15( on)-81( the)]TJ
0 -1.455 TD
[(surface)-79( of)-48( platelets,)-86( monocytes,)-39( neutrophils,)-76( and some)-9( types)-7( of)-48( T)-52(-)-1(cells,)-79( and makes)-74( up)-71( a)-20( large)-80( portion)-62( of)]TJ
T*
[(endothelial)-8( cell)-9( intercellular)-58( junctions.)-1( CD31)-84( is)-52( implicated)-66( in)-31( several)-72( functions,)-56( including)-72( transendothelial)]TJ
0 -1.455 TD
[(migration)-11( of)-48( leukocytes,)-78( angiogenesis,)-5( and integrin)-17( activation.)-6( Tyr)-12(-)-1(690)-89( plays)-22( a)-20( critical)-81( role)-69( in)-31( leukocyte)]TJ
0 -1.455 TD
[(transendothelial)-58( migration)-11( \(TEM\))-45( and is)-52( required)-62( for)-52( efficient)-46( trafficking)-72( of)-48( CD31)-84( to)-32( and from)-30( the)-36( lateral)-90( border)]TJ
T*
[(recycling)-34( compartment)-35( \(LBRC\))-16( and is)-52( also)-75( essential)-90( for)-52( the)-36( LBRC)-55( membrane)-90( to)-32( be)-12( targeted)-16( around)-85( migrating)]TJ
T*
[(leukocytes.)-78( CD31)-84( prevents)-17( phagocyte)-85( ingestion)-24( of)-48( closely)-68( apposed)-28( viable)-76( cells)-18( by)-40( transmitting)-64( 'detachment')]TJ
0 -1.455 TD
[(signals,)-75( and changes)-9( function)-77( on)-81( apoptosis,)-70( promoting)-32( tethering)-22( of)-48( dying)-63( cells)-18( to)-32( phagocytes)-3( \(the)-17( encounter)-31( of)-48( a)]TJ
0 -1.455 TD
[(viable)-76( cell)-9( with)-46( a)-20( phagocyte)-85( via)-21( the)-36( homophilic)-75( interaction)-70( of)-48( CD31)-84( on)-81( both)-12( cell)-10( surfaces)-87( leads)-85( to)-32( the)-36( viable)-76( cell's)]TJ
0 -1.455 TD
[(active)-63( repulsion)-89( from)-30( the)-37( phagocyte.)-55( During)-64( apoptosis,)-70( the)-36( inside)-4(-)-1(out)-19( signaling)-29( of)-48( CD31)-84( is)-52( somehow)-75( disabled)-22( so)]TJ
0 -1.455 TD
[(that)-67( the)-36( apoptotic)-16( cell)-9( does)-23( not)-19( actively)-64( reject)-56( the)-36( phagocyte)-85( anymore.)-29( The)-59( lack)-14( of)-48( this)-69( repulsion)-89( signal)-5( together)]TJ
0 -1.455 TD
[(with)-46( the)-36( interaction)-70( of)-48( the)-36( eat)-70(-)-1(me)-89( signals)-14( and their)-84( respective)-86( receptors)-73( causes)-38( the)-37( attachment)-5( of)-48( the)-37( apoptotic)]TJ
0 -1.455 TD
[(cell)-9( to)-32( the)-36( phagocyte,)-55( thus)-13( triggering)-18( the)-37( process)-29( of)-48( engulfment\).)-41( CD31)-84( has)-16( been)-19( used)-8( to)-32( measure)-37( angiogenesis)]TJ
T*
[(in)-31( association)-70( with)-46( tumor)-1( recurrence.)-92( Other)-59( studies)-90( have)-75( also)-75( indicated)-32( that)-67( CD31)-83( and CD34)-84( can)-1( be)-12( used)-8( as)]TJ
0 -1.455 TD
[(markers)-81( for)-52( myeloid)-37( progenitor)-77( cells)-18( and recognize)-73( different)-5( subsets)-55( of)-48( myeloid)-36( leukemia)-69( infiltrates)-3( \(granular)]TJ
0 Tw 0 -1.455 TD
(sarcomas\).)Tj
/TT1 1 Tf
0 -1.909 TD
(Purification:)Tj
/TT0 1 Tf
-0.04 Tw 6.727 -0.091 Td
[(Was)-36( purified)-38( by)-40( Protein)-81( A)-36( and peptide)-90( affinity)-82( chromatography.)]TJ
/TT1 1 Tf
0 Tw -6.727 -2 Td
(Storage:)Tj
/TT0 1 Tf
-0.04 Tw 0 -1.455 TD
[(Aqueous)-34( buffered)-15( solution)-14( containing)-88( 100ug/ml)-73( BSA,)-42( 50%)-22( glycerol)-56( and less)-80( than)-25( 0.09%)-82( sodium)-13( azide.)-56( Store)-44( at)-50( -)]TJ
0 -1.455 TD
[(20\260C)-18( for)-52( 12)-90( months.)-54( Protect)-73( from)-30( light.)-67( [Product)-75( without)-66( BSA)-72( and/or)-79( sodium)-13( azide)-87( is)-52( available)-70( for)-52( special)-31( order.])]TJ
/TT1 1 Tf
0 Tw 0 -1.909 TD
(Reconstitution:)Tj
/TT0 1 Tf
-0.04 Tw 0 -1.455 TD
[(If)-36( the)-36( antibody)-25( is)-52( in)-31( liquid)-13( form,)-91( no)-81( reconstitution)-78( needed.)]TJ
0 -2.909 TD
[(Reconstitution)-90( is)-52( only)-81( required)-62( for)-52( the)-36( lyophilized)-45( antibody.)-86( Please)-15( refer)-92( to)-32( the)-37( reconstitution)-78( instruction)-26( card)-10( in)]TJ
0 -1.455 TD
[(the)-36( package.)]TJ
/TT1 1 Tf
0 Tw 54.182 53.091 Td
(Size:)Tj
/TT0 1 Tf
3 -0.091 Td
(100ul)Tj
/TT1 1 Tf
-3 -2.818 Td
(Concentration:)Tj
/TT0 1 Tf
8.091 -0.091 Td
(1ug/uL)Tj
/TT1 1 Tf
-8.091 -2.818 Td
(Host:)Tj
/TT0 1 Tf
3.273 -0.091 Td
(Rabbit)Tj
/TT1 1 Tf
-3.273 -1.909 Td
(Reactivities:)Tj
0.2 scn
/TT0 1 Tf
6.6416 0 0 6.6416 424.437 623.1191 Tm
(Human,Mouse,Rat,Dog,Pig,Rabbit,Sheep,)Tj
0 scn
/TT1 1 Tf
7.3058 0 0 7.3058 424.437 609.1717 Tm
(Application:)Tj
ET
q
10 36 575 780 re
W n
q 1 0 0 1 434.3994 591.5714 cm
0 0 m
0 1.328 -1.992 1.328 -1.992 0 c
-1.992 -1.328 0 -1.328 0 0 c
f
Q
Q
BT
/TT0 1 Tf
7.3058 0 0 7.3058 441.041 589.911 Tm
[(IF\(1:100)-3(-)-1(500\))]TJ
ET
q
10 36 575 780 re
W n
q 1 0 0 1 434.3994 580.9448 cm
0 0 m
0 1.328 -1.992 1.328 -1.992 0 c
-1.992 -1.328 0 -1.328 0 0 c
f
Q
Q
BT
/TT0 1 Tf
-0.04 Tw 7.3058 0 0 7.3058 441.041 579.2844 Tm
[(Not)-1( yet)-6( tested)-8( in)-31( other)-43( applications.)]TJ
T*
[(Optimal)-36( working)-62( dilutions)-48( must)-4( be)]TJ
0 -1.455 TD
[(determined)-86( by)-40( the)-36( end)-90( user.)]TJ
/TT1 1 Tf
-0.02 Tw -2.273 -3.818 Td
[(Antibody)-48( Type:)]TJ
/TT0 1 Tf
0 Tw 8.182 -0.091 Td
(Polyclonal)Tj
/TT1 1 Tf
-8.182 -1.909 Td
(Isotype:)Tj
0.2 scn
/TT0 1 Tf
6.6416 0 0 6.6416 467.6075 515.5248 Tm
(IgG)Tj
0 scn
/TT1 1 Tf
-0.02 Tw 7.3058 0 0 7.3058 424.437 501.5775 Tm
[(Molecular)-1( Weight:)]TJ
0.2 scn
/TT0 1 Tf
0 Tw 6.6416 0 0 6.6416 503.4723 501.5775 Tm
(82kDa)Tj
0 scn
/TT1 1 Tf
7.3058 0 0 7.3058 424.437 487.6301 Tm
(Note:)Tj
/TT0 1 Tf
0.021 Tw 5.9775 0 0 5.9775 424.437 460.3994 Tm
[(For)-20( )1(research)-16( )1(use)-25( )1(only.)-91( )1(CAUTION:)-13( )1(Not)-12( )1(for)-1( )1(human)-72( )1(or)]TJ
0 -1.333 TD
[(animal)-94( )1(therapeutic)-36( )1(or)-97( )1(diagnostic)-13( )1(use.)]TJ
ET
q
/GS0 gs
564.5375671 0 0 -0.6641693 15.3132935 706.8034821 cm
/Im1 Do
Q
BT
/TT0 1 Tf
0 Tw 10.6266 0 0 10.6266 21.2908 81.8272 Tm
( )Tj
ET
q
10 36 575 780 re
W n
/CS3 cs 0.302 0.306 0.333 scn
q 1 0 0 1 19.2983 691.5278 cm
0 0 m
0 1.771 -2.657 1.771 -2.657 0 c
-2.657 -1.771 0 -1.771 0 0 c
f
Q
Q
BT
/CS3 cs 0.302 0.306 0.333 scn
/TT1 1 Tf
-0.007 Tw 9.2983 0 0 9.2983 28.5965 688.8711 Tm
[(Rabbit)-50( Anti)-28(-)-69(CD31)-16( Polyclonal)-4( Antibody,)-47( Alexa)-2( Fluor)-69( 647)-18( conjugated)]TJ
ET
q
/GS0 gs
99.6242828 0 0 -75.050293 25.2757263 285.7248688 cm
/Im2 Do
Q
BT
/CS0 cs 0 scn
/TT0 1 Tf
0 Tw 10.6266 0 0 10.6266 25.2757 201.3763 Tm
( )Tj
ET
q
/GS0 gs
99.6242828 0 0 -75.050293 153.4589691 285.7248688 cm
/Im3 Do
Q
BT
/TT0 1 Tf
10.6266 0 0 10.6266 153.459 201.3763 Tm
( )Tj
12.125 0 Td
( )Tj
-24.187 -2.25 Td
( )Tj
12.063 0 Td
( )Tj
12.125 0 Td
( )Tj
-24.187 -2.25 Td
( )Tj
12.063 0 Td
( )Tj
12.125 0 Td
( )Tj
-0.04 Tw 7.3058 0 0 7.3058 26.604 121.6769 Tm
[(For)-30( full)-30( size)-82( images)-63( and description)-26( please)-13( click)-31( )]TJ
/CS3 cs 0 0.6 0.8 scn
0 Tw 6.6416 0 0 6.6416 180.6896 121.6769 Tm
(HERE)Tj
/CS0 cs 0 scn
7.3058 0 0 7.3058 197.2936 121.6769 Tm
(.)Tj
ET
q
/GS0 gs
0.6641693 0 0 -597.7456512 410.4896088 706.1392975 cm
/Im4 Do
Q
q
/GS0 gs
5.9774628 0 0 -40.5138702 569.888443 120.3485565 cm
/Im5 Do
Q
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
(7]Ӆ*97)
endobj
26 0 obj
<>stream
Hy\E323#3
P̴,HLEK"+E+2VTD%EH# }wfwfvvc_3?{feޝ@HHHHHH*豘V]
zן)@-9.q2BÇEڂ8g "2vn>u2]/Yz \S@ 7.M&p?o9v 0'rKś-;(Au.J%% %&˶0>6`TxOzzo(VDY*AZp ËgAs^.㮌+2Ȱ$E['FC:OMCIVVDD3}`u߈buߨɴ4қԭV^V0XF ϓ@i|Y|.?i'3}Ŵ+ޘaa:
3g},F"kNɳՕx57,H)X7*v/Mո+(fWr=WӃJcߓtG16sPt:t"9G
if
3do\ˢ|c:1&<ЭWnPdq0IRgu~惘n9BWV2T6~}rs4h-D.sgV/n3;q@hThI*jTJqJK2c!QT7;60
5NoJݻ'rBP%ȍ4
P(/CJC1
9eڴ}5S{"wty@P5e*Zg~?S(Sɗ,ʽv 2[̋t_Z\d&}/2YϹO&y#
?P>,0P-
asds[U꼩\=T~)S>B,gk$7+j0?60<&uźg
A]_@en%Mȝ~5PSu$^2s0RSPw L9٦n9$vڣ=f#g 7,Oa
:ܾ.4+H!=MvF(G|YU
ITR)>@✧*[j5KoB{Kp,`姙$JO궒jvż@r3`w\A%jSx+>m;5ا@._1:T#q]wrTC8r:lU4P}~Y]XwJ~b:YQϗLP-X_ֻа2$ݥC=~P]VҘLhu?S'\C:7"4dD*%9 Ogfe\OLoTy5Qkj.84,: t:_YON3˃:O/r犁3t!Psbty{aETu7nMѶ f+^Y6zHic?R%+C,γL =ZJ1H+,x^
I!u2{5x_@LI6[w5LN5:xXoEgf9tu=yùw=aґza*҃K`驪eP/y*sσn3N{ME\8g: *fz#W??L